Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mucormycosis is a rare but devastating fungal infection primarily affecting immunocompromised patients such as those with hematological malignancy, bone marrow and solid organ transplantation, and patients with diabetes, and, even more rarely, immunocompetent patients. The objective of this study was to assess the prevalence and burden, both clinical and economic, of mucormycosis among hospitalized patients in the U.S. METHODS: Comparative Database, with more than 560 participating hospitals covering 104 million patients (January 2005-June 2014). All hospitalizations in the database were evaluated for the presence of mucormycosis using either an ICD-9 code of 117.7 or a positive laboratory result for Mucorales. Hospitalizations were further required to have prescriptions of amphotericin B or posaconazole to be considered as mucormycosis-related hospitalizations. The prevalence of mucormycosis-related hospitalizations among all hospital discharges was estimated. Mortality rate at discharge, length of hospital stay, and readmission rates at 1 and 3 months were evaluated among mucormycosis-related hospitalizations. Cost per hospital stay and average per diem cost (inflated to 2014 USD) were reported. RESULTS: The prevalence of mucormycosis-related hospitalizations was estimated as 0.12 per 10,000 discharges during January 2005-June 2014. It increased to 0.16 per 10,000 discharges if the definition of mucormycosis was relaxed to not require the use of amphotericin B or posaconazole. The median length of stay was 17 days, with 23% dead at discharge; readmission rates were high, with 30 and 37% of patients readmitted within one and three months of discharge, respectively. The average cost per hospital stay was $112,419, and the average per diem cost was $4,096. CONCLUSIONS: The study provides a recent estimate of the prevalence and burden of mucormycosis among hospitalized patients. The high clinical and economic burden associated with mucormycosis highlights the importance of establishing active surveillance and optimizing prophylactic and active treatment in susceptible patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other studies also support our findings that mucormycosis, though a rare disease, consistently results in high average hospitalization costs (>$100,000 in this study) due to its severity and long length of stay [10, 22].”
From Estimation of Direct Healthcare Costs of Fungal Diseases in the United States (2019) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Self-citationRibes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711 · cited 1×
“7 (either primary or secondary) or a positive laboratory microbiology result for Mucorales, the organisms that cause mucormycosis [10].”
BackgroundESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429 · cited 1×
“With the improvement in the care of critically ill and immunocompromised patients in the past few years, the prevalence of invasive fungal infections, including mucormycosis, might have changed [1, 3, 6, 7].”
BackgroundRees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 3×
“7 mucormycosis cases per million individuals per year in the San Francisco Bay Area between 1992 and 1993 [3].”
BackgroundKontoyiannis, D. P., & Lewis, R. E. (2011) · Blood · doi:10.1182/blood-2011-03-316430 · Cited by 376 · cited 2×
“Due to lack of time stamps of the drug prescriptions, it was not clear if these fluconazole and voriconazole prescriptions were intended to treat mucormycosis or were intended to serve as prophylaxis treatment for patients with high risk of various invasive fungal infections, such as patients with leukemia and recipie…”
BackgroundSelf-citationSkiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006
Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., et al. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110087 · Cited by 321 · cited 1×
“29% in patients undergoing solid organ transplants and hematopoietic cell transplants, respectively, during 2001-2006 [4].”
BackgroundSelf-citationMousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Cited by
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
“It is claimed that regular statin use in diabetic patients has brought down diabetes as a risk factor for mucormyc sis in the United States [68], though a case series from the same country reported diabetes as risk factor in 52% cases of mucormycosis [14].”
BackgroundInfluentialEpidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
“The exact incidence/prevalence is not known because there are few population-based studies [3,15,18], and they differ in capture periods, populations and definition or diagnostic procedures.”
BackgroundEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
“Other studies also support our findings that mucormycosis, though a rare disease, consistently results in high average hospitalization costs (>$100 000 in this study) due to its severity and long length of stay [10, 22].”
ResultEpidemiology of Mucormycosis in India
Prakash, H., & Chakrabarti, A. (2021) · Microorganisms · doi:10.3390/microorganisms9030523 · Cited by 441
A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment
Prakash, H., Ghosh, A. K., Rudramurthy, S. M., Singh, P., Xess, I., Savio, J., Pamidimukkala, U., Jillwin, J., Varma, S., Das, A., et al. (2019) · Medical Mycology · doi:10.1093/mmy/myy060 · Cited by 389
Metadata
- Authors
- Kontoyiannis, D. P., Yang, H., Song, J., Kelkar, S. S., Yang, X., Azie, N., Harrington, R., Fan, A., Lee, E., & Spalding, J. R.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Analysis Group (United States) (US)
- Astellas Pharma (United States) (US)
- Corresponding author
- Kontoyiannis, Dimitrios P.
- ORCID
- Venue
- BMC Infectious Diseases
- Published
- 2016-12
- Volume
- 16
- Issue
- 1
- Pages
- 730-730
- ISSN
- 1471-2334 (ISSN-L)
- PMC
- PMC5134281
- OpenAlex
- W2557575310
- Semantic Scholar
- fc8c4987bf72e7c10ff35b2e254765906e6843a1
- Cited by
- 132
- References
- 27
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 13 · 2023: 15 · 2022: 18 · 2021: 21 · 2020: 8 · 2019: 17 · 2018: 13 · 2017: 8
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Infectious Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Astellas Pharma Global Development (NA)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
- Keywords
- mucormycosis, Mucorales, prevalence, hospitalization burden, economic burden, mortality, length of hospital stay, hospital readmission, health care costs, amphotericin B, posaconazole, immunocompromised patients, hospitalized patients
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Child, Female, Hospitalization, Humans, Length of Stay, Male, Middle Aged, Mucormycosis, Retrospective Studies, United States, Prevalence, Databases, Factual, Cost of Illness, Hospital Costs, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. https://app.cochat.ai/papers/10.1186/s12879-016-2023-z
- The paper
- Kontoyiannis, D. P., Yang, H., Song, J., Kelkar, S. S., Yang, X., Azie, N., Harrington, R., Fan, A., Lee, E., & Spalding, J. R. (2016). Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-016-2023-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Fig. 1 Prevalence of mucormycosis-related hospitalizations. Note: [1] Mucormycosis encounters with drug restriction were identified using ICD-9 codes or laboratory results and required at least one use of amphotericin B or posaconazole](https://figures.cochat.ai/paper-figures/e8cb9e8c4d284e5890a1afcf486e0853/prevalence-clinical-and-economic-burden-of-mucormycosis-related-hospitalizations-figure-1.jpg)